Core Viewpoint - Nearshore Protein, established in September 2009 and listed on the Shanghai Stock Exchange in September 2022, is a leading provider of protein and related technology services in China, specializing in the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with related technical services [1]. Financial Performance - For Q3 2025, Nearshore Protein reported revenue of 112 million yuan, ranking 33rd in the industry, significantly lower than the industry leader Changchun High-tech's 9.807 billion yuan and second-ranked Kanghong Pharmaceutical's 3.624 billion yuan, as well as below the industry average of 1.26 billion yuan and median of 734 million yuan [2]. - The main business composition includes target and factor proteins at 41.846 million yuan (58.04%), enzymes and reagents at 18.475 million yuan (25.63%), CRO services at 8.555 million yuan (11.87%), recombinant antibodies at 1.928 million yuan (2.67%), and others at 1.291 million yuan (1.79%) [2]. - The net profit for Q3 2025 was -28.8593 million yuan, ranking 27th in the industry, far below the industry leader Tonghua Dongbao's 1.188 billion yuan and second-ranked Changchun High-tech's 1.06 billion yuan, as well as below the industry average of 166 million yuan and median of 56.6337 million yuan [2]. Financial Ratios - As of Q3 2025, Nearshore Protein's debt-to-asset ratio was 5.23%, up from 4.85% in the previous year, which is significantly lower than the industry average of 26.88%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 64.84%, slightly up from 64.54% year-on-year, but still below the industry average of 70.17% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.65% to 6,094, while the average number of circulating A-shares held per household increased by 5.99% to 5,361.9 [5]. - Among the top ten circulating shareholders, Huashang Lexiang Flexible Allocation Mixed A ranked third with 604,700 shares, down by 14,800 shares from the previous period [5].

Core Viewpoint - Shenzhou Cell is a leading innovative biopharmaceutical company in China, focusing on the research and development of biological drugs across various therapeutic areas, including malignant tumors and autoimmune diseases [1] Group 1: Business Performance - For Q3 2025, Shenzhou Cell reported revenue of 1.312 billion yuan, ranking 10th among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was -251 million yuan, placing the company 31st in the industry, while the top performer, Tonghua Dongbao, achieved a net profit of 1.188 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Shenzhou Cell's debt-to-asset ratio was 101.46%, a decrease from 104.24% year-on-year, but still significantly higher than the industry average of 26.88%, indicating substantial debt pressure [3] - The gross profit margin for the same period was 94.09%, slightly down from 96.28% year-on-year, yet above the industry average of 70.17%, reflecting strong profitability potential [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 40.96% to 13,700, while the average number of circulating A-shares held per shareholder decreased by 29.06% to 32,400 [5] - Notable changes among the top ten circulating shareholders include the entry of Hong Kong Central Clearing Limited and the South China CSI 500 ETF, while the China Europe Medical Health Mixed A fund exited the list [5] Group 4: Market Outlook - According to West Securities, Shenzhou Cell's revenue in the first half of 2025 was below expectations due to price reductions from centralized procurement and medical insurance controls affecting its core product, Anjiah [6] - Despite challenges, the company is expected to see growth from new products and a stable increase in sales of other antibody drugs, with projected revenues for 2025-2027 of 2.194 billion, 2.543 billion, and 3.021 billion yuan, respectively [6] - Zhongyou Securities anticipates a revenue increase in 2024, with a forecast of 2.827 billion yuan for 2025, and a net profit of 223 million yuan, maintaining a "buy" rating [6]

Core Viewpoint - Eddie Pharmaceutical is an innovative company in the domestic anti-HIV drug sector, focusing on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] Group 1: Business Performance - For Q3 2025, Eddie Pharmaceutical reported revenue of 552 million yuan, ranking 21st among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The company's net profit for the same period was 16.11 million yuan, ranking 22nd in the industry, with the top performer, Tonghua Dongbao, achieving a net profit of 1.188 billion yuan [2] - The main business composition includes human-derived proteins at 149 million yuan (41.11%), new drugs at 129 million yuan (35.69%), diagnostic equipment and reagents at 49.35 million yuan (13.62%), and generic drugs at 34.31 million yuan (9.47%) [2] Group 2: Financial Ratios - As of Q3 2025, Eddie Pharmaceutical's debt-to-asset ratio was 41.35%, higher than the previous year's 40.23% and above the industry average of 26.88% [3] - The gross profit margin for the same period was 65.72%, an increase from 52.81% year-on-year, but still below the industry average of 70.17% [3] Group 3: Executive Compensation - The chairman, Fu Helian, received a salary of 1.1336 million yuan in 2024, an increase of 13,900 yuan from 2023 [4] - The president, Zhang Jie, earned 3.7593 million yuan in 2024, up by 745,800 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.55% to 12,100, with an average holding of 34,700 circulating A-shares, a decrease of 1.53% [5] - New significant shareholders include Xingquan Commercial Model Mixed A and Huatai-PineBridge Healthcare Mixed, while some previous top shareholders have exited [5] Group 5: Growth Prospects - In the first half of 2025, Eddie Pharmaceutical's revenue grew by 100.19% year-on-year to 362 million yuan, with a net profit of 9.19 million yuan, marking a turnaround from losses [6][7] - Key growth drivers include the recovery of sales from the already launched product, Ainomi, and the expansion of the HIV drug business [6] - The company is advancing its research on the ACC017 enzyme inhibitor and plans to submit IND applications for long-acting HIV prevention drugs by the end of 2025 [6][7]

Core Viewpoint - Ganli Pharmaceutical is a leading company in the field of recombinant insulin analogs, showcasing strong financial performance and innovative drug development capabilities [1][6][7]. Financial Performance - For Q3 2025, Ganli Pharmaceutical reported revenue of 3.047 billion yuan, ranking third among 34 companies in the industry, with a net profit of 818 million yuan, placing fourth [2]. - The company's revenue from biological products accounted for 95.05% of total revenue, while medical devices and other income contributed 4.69% [2]. - The company achieved a year-on-year revenue growth of 57.18% in the first half of 2025, with a net profit growth of 101.96% [6]. Profitability and Debt Management - As of Q3 2025, Ganli Pharmaceutical's debt-to-asset ratio was 7.09%, significantly lower than the industry average of 26.88%, indicating strong debt management [3]. - The gross profit margin for the same period was 76.18%, higher than the industry average of 70.17%, reflecting robust profitability [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 22.53% to 94,700, while the average number of shares held per shareholder decreased by 17.81% [5]. Leadership and Compensation - The chairman and general manager, Chen Wei, received a salary of 924,400 yuan in 2024, an increase of 32,200 yuan from the previous year [4]. Innovation and R&D - Ganli Pharmaceutical has several innovative drugs in development, including GZR4 and GZR102, which are in various clinical trial phases and show potential for market expansion [7]. - The company invested 5.52 billion yuan in R&D in the first half of 2025, representing 26.70% of its revenue, indicating a strong commitment to innovation [6].

Core Viewpoint - Aopumai, a leading company in the cell culture products and services sector in China, has shown significant growth potential despite its current lower ranking in revenue and profit compared to industry leaders [1][2]. Group 1: Company Overview - Aopumai was established on November 27, 2013, and was listed on the Shanghai Stock Exchange on September 2, 2022, with its headquarters in Shanghai [1]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and has a comprehensive industry chain and technological research advantages [1]. Group 2: Financial Performance - For Q3 2025, Aopumai reported revenue of 272 million yuan, ranking 28th out of 34 in the industry, significantly lower than the top competitors [2]. - The revenue composition includes product revenue of 155 million yuan (87.34%), service revenue of 22.27 million yuan (12.53%), and other revenue of 0.233 million yuan (0.13%) [2]. - The net profit for the same period was 49.06 million yuan, ranking 18th in the industry, again trailing behind leading companies [2]. Group 3: Financial Ratios - Aopumai's debt-to-asset ratio stood at 7.59% in Q3 2025, slightly up from 7.00% year-on-year, but well below the industry average of 26.88%, indicating strong solvency [3]. - The gross profit margin was reported at 54.57%, down from 57.45% year-on-year and below the industry average of 70.17%, suggesting room for improvement in profitability [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 14.63% to 3,682, with an average holding of 30,800 shares, up 27.96% [5]. - Notable changes among the top ten circulating shareholders include increases in holdings by several funds, indicating growing investor interest [5]. Group 5: Future Outlook - Aopumai is expected to see revenue growth in the coming years, with projected revenues of 379 million yuan, 473 million yuan, and 586 million yuan for 2025, 2026, and 2027, respectively [5]. - The net profit forecasts for the same years are 87 million yuan, 107 million yuan, and 134 million yuan, reflecting a positive growth trajectory [5].

Core Viewpoint - 康辰药业 is a significant player in the domestic innovative drug sector, focusing on R&D and clinical needs, with products like "苏灵" and "密盖息" [1] Group 1: Financial Performance - In Q3 2025, 康辰药业 achieved revenue of 692 million yuan, ranking 18th in the industry, significantly lower than the top competitors [2] - The main revenue contributor, "苏灵," generated 326 million yuan, accounting for 70.77% of total revenue [2] - The net profit for the same period was 134 million yuan, ranking 11th in the industry, below the average of 166 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, 康辰药业's debt-to-asset ratio was 13.92%, which is lower than the industry average of 26.88%, indicating lower debt pressure [3] - The gross profit margin was 90.15%, higher than the industry average of 70.17%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.18% to 10,700 [5] - The average number of shares held per shareholder decreased by 6.12% to 14,800 [5] Group 4: Product Pipeline and Future Outlook - 康辰药业's product pipeline includes promising candidates like KC1036 and KC1086, with projected peak sales for KC1036 potentially exceeding 2 billion yuan [5] - Revenue projections for 2025-2027 are estimated at 936 million, 1.046 billion, and 1.174 billion yuan, with net profits of 144 million, 185 million, and 204 million yuan respectively [5] - The company is expected to leverage the success of "苏灵" and continue its digital transformation [6]

证券代码：600867 证券简称：通化东宝 公告编号：2025-075 通化东宝药业股份有限公司 关于控股股东增持公司股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：通化东宝药业股份有限公司（以下简称"公司"、 "通化东宝"）于 2024 年 10 月 30 日收到控股股东东宝实业集团股份有限公司（以 下简称"东宝集团"）增持股份计划的通知。基于对公司未来发展前景的信心和 对公司价值的高度认可，控股股东东宝集团计划自 2024 年 10 月 31 日起，通过 上海证券交易所以集中竞价交易方式增持公司股份。本次增持比例不低于公司总 股本 1%，即 19,817,341 股，不超过公司总股本 2%，即 39,634,681 股。若增持 计划实施期间，公司发生有送股、资本公积金转增股本、股份回购注销等股份变 动事项，则对增持数量进行相应调整。实施期限为自 2024 年 10 月 31 日之日起 12 个月内（即 2024 年 10 月 31 日至 2025 年 10 月 3 ...

关于通化东宝药业股份有限公司 控股股东增持公司股份的 法律意见书 致：通化东宝药业股份有限公司 吉林秉责律师事务所(以下简称"本所")接受通化东宝药业股份 有限公司（以下简称"通化东宝"或"公司"）的委托，指派本所律 师对公司控股股东东宝实业集团股份有限公司（以下简称"东宝集 团"）增持公司股份（以下简称"本次增持"）事宜实施专项核查并 出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证 券法》"）《律师事务所从事证券法律业务管理办法》和《律师事务 所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以 前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责 和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定 的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在 虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 吉林秉责律师事务所 （一）增持主体的基本情况 本次增持的增持主体为公司控股股东东宝集团，本所律师核查， 截至本法律意见书出具之日，增持主体的基本情况如下： 本法律意见书根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《证券法》《上市 ...

Core Viewpoint - Tonghua Dongbao announced a share buyback plan, reflecting confidence in the company's future development and recognition of its value [1] Group 1: Share Buyback Details - The company plans to repurchase a total of 27.8014 million shares, which represents 1.42% of the current total share capital [1] - The total amount allocated for the buyback is approximately 228.0059 million yuan [1] - Following the buyback, the shareholding ratio of Dongbao Group and its concerted parties will increase from 31.06% to 32.75% [1] Group 2: Implementation and Control - The buyback plan has been fully implemented without causing any changes in the company's controlling shareholder or actual controller [1]

Summary of Key Points Core Viewpoint - As of October 30, 4271 companies have released their Q3 2025 reports, with 2318 companies showing year-on-year profit growth, while 1953 companies reported a decline. Additionally, 2534 companies experienced revenue growth, and 1737 companies saw a decrease. Notably, 1768 companies had both profit and revenue growth, while 1187 companies reported declines in both metrics. There are 547 companies with profit growth exceeding 100%, with Fangzheng Electric showing the highest increase at 153128.60% [1]. Financial Performance Overview - **Profit Growth**: 2318 companies reported a year-on-year increase in net profit, while 1953 companies experienced a decline [1]. - **Revenue Growth**: 2534 companies saw an increase in operating revenue, whereas 1737 companies reported a decrease [1]. - **Simultaneous Growth**: 1768 companies had both net profit and operating revenue growth, indicating a positive trend in performance for a significant number of firms [1]. - **Decline in Performance**: 1187 companies reported declines in both net profit and operating revenue, highlighting potential challenges faced by these firms [1]. Notable Companies - **Fangzheng Electric**: Achieved the highest net profit growth of 153128.60% with a net profit of 1375.73 million and operating revenue of 201253.53 million [1]. - **Jingrui Materials**: Reported a net profit of 12836.85 million with a year-on-year growth of 19202.65%, and operating revenue growth of 118684.44% [1]. - **Hengyu Environmental**: Showed a net profit of 1446.17 million, with a significant year-on-year growth of 17879.81% and operating revenue growth of 191.99% [1]. - **ST Weier**: Reported a net profit of 19534.45 million with a year-on-year increase of 15294.42% and operating revenue growth of 6.44% [1]. Additional Insights - Companies like Nanji Light and Huahong Technology also reported substantial growth in both net profit and operating revenue, indicating a robust performance in certain sectors [1]. - The data reflects a mixed performance across various industries, with some companies thriving while others face declines, suggesting a diverse landscape in the current market [1].